NYSE · Healthcare · Medical Devices · USA
Glaukos Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
Glaukos develops and sells eye care products addressing glaucoma, corneal conditions, and retinal disease. The company's offerings include micro-scale surgical devices for glaucoma treatment, long-acting drug implants for intraocular delivery, bioactivated corneal therapies, transdermal eyelid medications, and sustained-release retinal implants. These solutions serve ophthalmologists and eye care professionals treating patients with chronic vision disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Glaukos Corp stock.
Overvalued: intrinsic value $20.13 per share, market price $166.96, margin of safety -729.4% (as of 2026-10-19).
A 1.6x revenue multiple, discounted for its losses, values the shares at $20.13; the price of $166.96 is 729% above that value.
Leak Score: 23/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
55 more in this industry show a wider margin of safety.
GKOS is overvalued (as of the 2026-10-19 close). A 1.6x revenue multiple, discounted for its losses, values the shares at $20.13; the price of $166.96 is 729% above that value.
$20.13 per share (as of the 2026-10-19 close), against a market price of $166.96. That is a margin of safety of -729.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
23 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.